Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea

Suven Life Sciences Ltd (Suven) has been granted five (5) product patents, three (3) from China (ZL 200580051550, ZL 200680039008 and ZL200780047442) and two (2) from Korea (1162482 and 1176892) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2027 and 2028 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of eight (8) granted patents from China & ten (10) granted patents from Korea. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Venkat Jasti, CEO of Suven.

The Suven Life Sciences Ltd stock was trading at Rs.33.85, up by Rs.0.75 or 2.27%. The stock hit an intraday high of Rs.35.25 and low of Rs.32.50.

The total traded quantity was 8.03 lakhs compared to 2 week average of 4.88 lakhs.

Source : Equity Bulls

Keywords